(PRNB) – StreetInsider.com Reports
-
Sanofi (SNY) Company, Principia Biophara Inc., Reports Early Conclusion of Patient Enrollment in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib
-
M&A spikes in record third quarter as boards go on pandemic deal spree
-
Sanofi (SNY) announces expiration of HSR waiting period for acquisition of Principia Biopharma (PRNB)
-
Sanofi (SNY) Announces $100/Sh Cash Tender Offer to Acquire Principia Biopharma Inc. (PRNB)
-
Biotechnology Value Fund said Principia Biopharma Inc. (PRNB) proposed sale to Sanofi would be a 'suboptimal and, frankly, sad outcome'
-
Stifel Downgrades Principia Biopharma (PRNB) to Hold
-
Guggenheim Downgrades Principia Biopharma (PRNB) to Neutral, Following Acquisition
-
Principia Biopharma (PRNB) PT Raised to $100 at Baird
-
SVB Leerink Downgrades Principia Biopharma (PRNB) to Market Perform
-
Pre-Open Stock Movers 08/17: (CVAC) (TCON) (GOLD) Higher; (SRNE) Lower (more...)
-
H.C. Wainwright Downgrades Principia Biopharma (PRNB) to Neutral
-
Sanofi (SNY) to Acquire Principia Biopharma (PRNB) for $100/Share, or $3.68B
-
Principia Biopharma Inc. (PRNB) IV into Sanofi (SNY) acquires for $3.68B
-
Sanofi in hunt for specialty drugs with $3.7 billion deal for U.S.-based Principia
-
Principia Biopharma (PRNB) PT Raised to $112 at SVB Leerink
-
Principia Biopharma (PRNB) PT Raised to $104 at Stifel, Following Earnings
-
Principia Biopharma (PRNB) PT Raised to $123 at Wells Fargo
-
Evercore ISI Starts Principia Biopharma (PRNB) at Outperform
-
Principia Biopharma Inc. (PRNB) Seen as Good Acquisition Bid for Sanofi - Guggenheim
-
Principia Biopharma Inc. (PRNB) call put ratio 2.6 calls to 1 put with focus on August calls as shares rally 11.5%
-
Sanofi (SNY) to study U.S. biotech targets, including Principia Biopharma Inc. (PRNB) - Bloomberg
-
Guggenheim Starts Principia Biopharma (PRNB) at Buy
-
Principia Biopharma Inc. (PRNB) Reports First Patient Enrolled in Sanofi (SNY) Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis
-
Principia Biopharma Inc. (PRNB) Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
-
Principia Biopharma Inc. (PRNB) Reports Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Biopharma (PRNB) PT Raised to $80 at SVB Leerink
-
Principia Biopharma (PRNB) PT Raised to $78 at Baird
-
Principia Biopharma (PRNB) PT Raised to $76 at Stifel
-
Principia Biopharma Inc. (PRNB) Mentioned Cautiously at Kerrisdale
-
Principia Biopharma (PRNB) PT Raised to $70 at H.C. Wainwright
-
Principia Biopharma (PRNB) PT Raised to $82 at Wells Fargo
-
Principia Biopharma Inc. (PRNB) new short at Kerrisdale Capital
-
Principia Biopharma (PRNB) PT Raised to $68 at BofA Securities
-
Principia Biopharma (PRNB) PT Lowered to $62 at H.C. Wainwright, Maintains 'Buy'
-
Principia Biopharma (PRNB) PT Raised to $63 at H.C. Wainwright
-
Principia Biopharma (PRNB) PT Raised to $66 at Stifel, Catalyst Could Add 75% to Share Price
-
Principia Biopharma (PRNB) PT Raised to $66 at Stifel
-
Principia Biopharma (PRNB) PT Raised to $63 at Wells Fargo
-
Principia Biopharma Inc. (PRNB) Highlights Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
-
Principia Biopharma (PRNB) PT Raised to $57 at H.C. Wainwright
-
Principia Biopharma Inc. (PRNB) Prices 7.5M Share Common Offering at $28/Sh
-
Principia Biopharma Inc. (PRNB) Commences $125M Public Offering of Common Stock
-
Principia Biopharma Inc. (PRNB) Announces Positive Preliminary Data of PRN1008 for ITP in Ongoing Phase 1/2 Trial
-
Principia Biopharma (PRNB) PT Raised to $51 at Stifel
-
Principia Biopharma Inc. (PRNB) Reports Positive Preliminary Data of PRN1008 from Ongoing Phase 2 Part B Trial in Pemphigus
-
Principia Biopharma (PRNB) Shares Could Reach Mid $50s If Phase 2 Data Is Positive - Stifel
-
Principia Biopharma Inc. (PRNB) Names Shawn Tomasello to Board
-
Principia Biopharma Inc. (PRNB) Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP
-
H.C. Wainwright Starts Principia Biopharma (PRNB) at Buy
-
Principia Biopharma Inc. (PRNB) Adds Patrick Machado to Board
Back to PRNB Stock Lookup